Intrathecal administration of mTOR inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncological diseases

摘要

An mTOR inhibitor for use in the treatment, by intrathecal administration, of selected pathologies among: tuberous sclerosis, Alzheimer's disease, primary progressive aphasia and multiple sclerosis, in which the mTOR inhibitor is everolimus.